Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Notes Payables (2016 - 2025)

Gsk has reported Notes Payables over the past 10 years, most recently at $4.0 billion for Q4 2025.

  • Quarterly results put Notes Payables at $4.0 billion for Q4 2025, up 32.36% from a year ago — trailing twelve months through Dec 2025 was $4.0 billion (up 32.36% YoY), and the annual figure for FY2025 was $4.0 billion, up 32.36%.
  • Notes Payables for Q4 2025 was $4.0 billion at Gsk, up from $3.0 billion in the prior quarter.
  • Over the last five years, Notes Payables for GLAXF hit a ceiling of $4.9 billion in Q4 2021 and a floor of $3.0 billion in Q4 2024.
  • Median Notes Payables over the past 5 years was $4.0 billion (2025), compared with a mean of $4.0 billion.
  • Biggest five-year swings in Notes Payables: dropped 24.68% in 2023 and later skyrocketed 32.36% in 2025.
  • Gsk's Notes Payables stood at $4.9 billion in 2021, then fell by 4.51% to $4.6 billion in 2022, then dropped by 24.68% to $3.5 billion in 2023, then decreased by 13.65% to $3.0 billion in 2024, then surged by 32.36% to $4.0 billion in 2025.
  • The last three reported values for Notes Payables were $4.0 billion (Q4 2025), $3.0 billion (Q4 2024), and $3.5 billion (Q4 2023) per Business Quant data.